1063 related articles for article (PubMed ID: 27827996)
1. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
2. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
5. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
Sartor GC; Powell SK; Brothers SP; Wahlestedt C
J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
[TBL] [Abstract][Full Text] [Related]
7. Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.
Werner MT; Wang H; Hamagami N; Hsu SC; Yano JA; Stonestrom AJ; Behera V; Zong Y; Mackay JP; Blobel GA
J Biol Chem; 2020 Feb; 295(7):1898-1914. PubMed ID: 31792058
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
9. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
Olp MD; Zhu N; Smith BC
Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
[TBL] [Abstract][Full Text] [Related]
10. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
12. The Functions of BET Proteins in Gene Transcription of Biology and Diseases.
Cheung KL; Kim C; Zhou MM
Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900
[TBL] [Abstract][Full Text] [Related]
13. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
[TBL] [Abstract][Full Text] [Related]
14. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW; Xing E; Larue RC; Li PK
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain inhibitors and cancer therapy: From structures to applications.
Pérez-Salvia M; Esteller M
Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
[TBL] [Abstract][Full Text] [Related]
16. JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states.
Handoko L; Kaczkowski B; Hon CC; Lizio M; Wakamori M; Matsuda T; Ito T; Jeyamohan P; Sato Y; Sakamoto K; Yokoyama S; Kimura H; Minoda A; Umehara T
Epigenetics; 2018; 13(4):410-431. PubMed ID: 30080437
[TBL] [Abstract][Full Text] [Related]
17. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
[TBL] [Abstract][Full Text] [Related]
18. The C-terminal domain of Brd2 is important for chromatin interaction and regulation of transcription and alternative splicing.
Hnilicová J; Hozeifi S; Stejskalová E; Dušková E; Poser I; Humpolíčková J; Hof M; Staněk D
Mol Biol Cell; 2013 Nov; 24(22):3557-68. PubMed ID: 24048450
[TBL] [Abstract][Full Text] [Related]
19. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
Wahi A; Manchanda N; Jain P; Jadhav HR
Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
[TBL] [Abstract][Full Text] [Related]
20. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
